Poole-Wilson P A, Robinson K
Cardiothoracic Institute, London, UK.
Cardiovasc Drugs Ther. 1989 Jan;2(6):733-41. doi: 10.1007/BF00133201.
Controversy continues concerning the use of digoxin as a positive inotropic agent in the treatment of heart failure in patients in sinus rhythm. Digoxin is properly used to control the heart rate in patients in atrial fibrillation. The findings from 14 uncontrolled and 6 controlled clinical trials have been examined. Digoxin does exert a small chronic positive inotropic effect. Although some individual patients, particularly those with fluid overload, appear to benefit from digoxin, controlled clinical trials in patients, most of whom have been treated with diuretics, have failed to demonstrate an increase of exercise capacity. No mortality trial has been attempted. Digoxin has the potential to be harmful in patients with ischemic heart disease. Alternative and safer therapies have been shown to be equal or superior to digoxin.
关于在窦性心律的心力衰竭患者中使用地高辛作为正性肌力药物仍存在争议。地高辛适用于控制心房颤动患者的心率。已对14项非对照和6项对照临床试验的结果进行了审查。地高辛确实会产生轻微的慢性正性肌力作用。尽管一些个体患者,特别是那些有液体超负荷的患者,似乎从地高辛中获益,但在大多数已接受利尿剂治疗的患者中进行的对照临床试验未能证明运动能力有所提高。尚未尝试进行死亡率试验。地高辛对缺血性心脏病患者可能有害。已证明替代的更安全疗法等同于或优于地高辛。